The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.

@article{Mistry2006TheAR,
  title={The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.},
  author={Nisha B Mistry and Arne S. Westheim and Sverre Erik Kjeldsen},
  journal={Expert opinion on pharmacotherapy},
  year={2006},
  volume={7 5},
  pages={
          575-81
        }
}
  • Nisha B Mistry, Arne S. Westheim, Sverre Erik Kjeldsen
  • Published in
    Expert opinion on…
    2006
  • Medicine
  • Valsartan is an angiotensin receptor antagonist that specifically blocks the angiotensin II type 1 receptors. It is an effective and well-tolerated once-daily antihypertensive agent, with a tolerability profile similar to placebo. A recent series of large-scale clinical trials have shown the benefits of valsartan in disease states beyond hypertension. Based on the results of the Val-HeFT (Valsartan in Heart Failure Trial) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) studies… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 23 CITATIONS

    Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

    VIEW 8 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    Is Entresto good for the brain?

    Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?

    VIEW 1 EXCERPT
    CITES BACKGROUND